Journal List > Korean J Gastroenterol > v.62(2) > 1007130

TOOLS
Kim: Is Classification of Gastric Cancer According to Distinct Therapeutic Targets Applicable in Clinical Practice?
Research Update

Korean J Gastroenterol 2013;62(2):140-141.

Published online: 4 October 2013

DOI: https://doi.org/10.4166/kjg.2013.62.2.140

Is Classification of Gastric Cancer According to Distinct Therapeutic Targets Applicable in Clinical Practice?

Kyoung-Mee Kim

Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Correspondence to: Kyoung-Mee Kim, Department of Pathology, Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea. Tel: +82-2-3410-2800, Fax: +82-2-3410-6396, E-mail: kkmkys@skku.edu

Copyright © 2013 Korean Ophthalmological Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

A Comprehensive Survey of Genomic Alterations in Gastric Cancer Reveals Systematic Patterns of Molecular Exclusivity and Co-occurrence among Distinct Therapeutic Targets

References

1. Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012; 61:673–684.
crossref
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–2917.
crossref
3. Bang YJ, Van Cutsem E, Feyereislova A, et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376:687–697.
crossref
4. Cheung DY, Kim JK. Perspectives of the stomach cancer treatment: the introduction of molecular targeted therapy and the hope for cure. Korean J Gastroenterol. 2013; 61:117–127.
crossref
5. Kwei KA, Bashyam MD, Kao J, et al. Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet. 2008; 4:e1000081.
crossref
TOOLS
Similar articles